Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Blood (2023) 142 (Supplement 1): 1702.

https://doi.org/10.1182/blood-2023-184898

Published: 2023

Journal Articles

Cutaneous T-Cell Lymphoma and Dupilumab Use: A Retrospective Matched Cohort Study of Clinical Characteristics and Treatment Outcomes

Robert Stuver, Stephen Dusza, Zachary D. Epstein-Peterson, Paola Ghione, William Johnson, Alison Moskowitz, Patricia Myskowski, Melissa Pulitzer, Steven M. Horwitz, Shamir Geller

Blood (2023) 142 (Supplement 1): 6184.

https://doi.org/10.1182/blood-2023-182223

Published: 2023

Journal Articles

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Blood (2021) 138 (26): 2828–2837.

https://doi.org/10.1182/blood.2021013379

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience

Blood (2021) 138 (Supplement 1): 2513.

https://doi.org/10.1182/blood-2021-151994

Published: 2021

Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4019.

https://doi.org/10.1182/blood-2019-125017

Published: 2019

Journal Articles

Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas

Alison J. Moskowitz, MD, Eric Jacobsen, MD, Jia Ruan, MD PhD, Jonathan H. Schatz, MD, Obadi Obadi, Kristin Motylinski, Christine Jarjies, MS, Natasha Galasso, Helen Hancock, NP, Theresa Davey, MPAS, Patricia Myskowski, MD, Ahmet Dogan, MD PhD, Giorgio Inghirami, MD, David M Weinstock, MD, Steven M. Horwitz, MD

Blood (2018) 132 (Supplement 1): 2922.

https://doi.org/10.1182/blood-2018-99-112123

Published: 2018

Journal Articles

Circulating Lymphoma Cells in Mycosis Fungoides/Sezary Syndrome Show Heterogeneity of the Cell-of-Origin and Variable PD-1 Expression By Flow Cytometric Analysis

Mariko Yabe, MD PhD, Natasha Lewis, MD, Qi Gao, Allison Sigler, Jeeyeon Baik, Melissa Pulitzer, MD, Patricia Myskowski, MD, Alison J. Moskowitz, MD, Steven M. Horwitz, MD, Ahmet Dogan, MD PhD, Mikhail Roshal, MD PhD

Blood (2018) 132 (Supplement 1): 1624.

https://doi.org/10.1182/blood-2018-99-119799

Published: 2018

Journal Articles

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Blood (2018) 132 (Supplement 1): 683.

https://doi.org/10.1182/blood-2018-99-115241

Published: 2018

Journal Articles

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Blood (2018) 131 (8): 888–898.

https://doi.org/10.1182/blood-2017-08-802470

Published: 2018

Includes: Supplemental data

Journal Articles

In Vitro , In Vivo , and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma

Alison J. Moskowitz, MD, Raphael Koch, MD, Neha Mehta-Shah, MD, Patricia Myskowski, MD, Meenal Kheterpal, MD, Ahmet Dogan, MD PhD, Theresa Davey, MPAS, Natasha Galasso, BA, Marzouk Evan, BA, Monica Shah, BA, Nivetha Ganesan, BS, Lakeisha Lubin, BS, Youn H. Kim, MD, Michael Khodadoust, MD PhD, Timothy Almazan, MD, Julia Dai, MD, Eric D. Jacobsen, MD, David M. Weinstock, MD, Steven M. Horwitz, MD

Blood (2017) 130 (Supplement 1): 819.

https://doi.org/10.1182/blood.V130.Suppl_1.819.819

Published: 2017

Journal Articles

A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B- and T-Cell Lymphomas

Blood (2017) 130 (Supplement 1): 821.

https://doi.org/10.1182/blood.V130.Suppl_1.821.821

Published: 2017

Journal Articles

Utility of Systemic Staging in Low Grade B-Cell Lymphomas Presenting in the Skin

Meenal Kheterpal, MD, Shamir Geller, MD, Julia Dai, MD, Melissa Pulitzer, MD, Patricia Myskowski, MD, Alison J. Moskowitz, MD, Jinah Kim, MD PhD, Richard T. Hoppe, MD, Youn H. Kim, MD, Steven M. Horwitz, MD

Blood (2017) 130 (Supplement 1): 2774.

https://doi.org/10.1182/blood.V130.Suppl_1.2774.2774

Published: 2017

Journal Articles

A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas

Blood (2016) 128 (22): 2991.

https://doi.org/10.1182/blood.V128.22.2991.2991

Published: 2016

Journal Articles

High-Depth, Targeted, Next Generation Sequencing Identifies Novel Genetic Alterations in Cutaneous T-Cell Lymphoma

Kimon V. Argyropoulos, MD, Steven M Horwitz, MD, Franck Rapaport, PhD, Enrico Velardi, PhD, Patricia Myskowski, MD, Christiane Querfeld, Melissa Pulitzer, MD, Ahmet Dogan, MD PhD, Meighan Gallagher, MA, Nicholas D. Socci, PhD, Ross L. Levine, MD, Minal Patel, BA, Natasha Galasso, Marcel van den Brink, MD PhD, Lia Palomba, MD

Blood (2015) 126 (23): 1485.

https://doi.org/10.1182/blood.V126.23.1485.1485

Published: 2015

Journal Articles

Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL)

David J. Straus, MD, Madeleine Duvic, MD, Steven M. Horwitz, MD, Kenneth B. Hymes, MD, Andre Goy, MD, Francisco J. Hernandez-Ilizaliturri, MD, Tatyana Feldman, MD, Brett Wegner, Patricia Myskowski, MD

Blood (2011) 118 (21): 882.

https://doi.org/10.1182/blood.V118.21.882.882

Published: 2011

Journal Articles

Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.

Steven M Horwitz, Youn H. Kim, MD, Francine M Foss, MD, Jasmine M. Zain, MD, Patricia Myskowski, MD, Mary Jo Lechowicz, MD, David C. Fisher, MD, Andrei Shustov, MD, Nancy L. Bartlett, MD, Maria L Delioukina, MD, Tony Koutsoukos, PhD, Steven M. Fruchtman, MD, Owen A. O'Connor, MD, PhD, Madeleine Duvic, MD

Blood (2010) 116 (21): 2800.

https://doi.org/10.1182/blood.V116.21.2800.2800

Published: 2010

Journal Articles

Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial.

Steven M. Horwitz, MD, Madeleine Duvic, MD, Youn Kim, MD, Jasmine M Zain, MD, Mary Jo Lechowicz, MD, Patricia Myskowski, MD, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 919.

https://doi.org/10.1182/blood.V114.22.919.919

Published: 2009

Journal Articles

Pralatrexate (PDX) IS Active in Cutaneous T-Cell Lymphoma: Preliminary Results of a Multi-Center Dose-Finding Trial.

Steven M. Horwitz, MD, Madeleine Duvic, MD, Youn Kim, MD, Jasmine M. Zain, MD, Mary Jo Lechowicz, MD, Patricia Myskowski, MD, Hanna Weissbrot, Danielle Wright, Lacey Chance, Tony Koutsoukos, Pablo Cagnoni, MD, Michael Saunders, MD, Owen A. O’Connor, MD, PhD

Blood (2008) 112 (11): 1569.

https://doi.org/10.1182/blood.V112.11.1569.1569

Published: 2008

Journal Articles

Bexarotene Is Highly Active in the Treatment of Subcutaneous Panniculitis-Like T-Cell Lymphoma.

Ana M. Molina, MD, Ranjana Advani, MD, Sunil Reddy, MD, Richard Hoppe, MD, Jonathan W. Friedberg, MD, Sara Sadan, MD, Patricia Myskowski, MD, Youn H. Kim, MD, Steven M. Horwitz, MD

Blood (2005) 106 (11): 3344.

https://doi.org/10.1182/blood.V106.11.3344.3344

Published: 2005

Journal Articles

Results of a Phase II Trial of Oral Bexarotene Combined with Interferon Alfa-2b for Patients with Cutaneous T-Cell Lymphoma (CTCL).

David J. Straus, M.D., Madeleine Duvic, M.D., Timothy Kuzel, M.D., Steven Horwitz, M.D., Marie-France Demierre, M.D., Patricia Myskowski, M.D., Kathleen Maignan, B.A., Steven Steckel, Pharm.D.

Blood (2004) 104 (11): 2644.

https://doi.org/10.1182/blood.V104.11.2644.2644

Published: 2004

NARROW

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Cutaneous T-Cell Lymphoma and Dupilumab Use: A Retrospective Matched Cohort Study of Clinical Characteristics and Treatment Outcomes

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas

Circulating Lymphoma Cells in Mycosis Fungoides/Sezary Syndrome Show Heterogeneity of the Cell-of-Origin and Variable PD-1 Expression By Flow Cytometric Analysis

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

In Vitro , In Vivo , and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma

A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B- and T-Cell Lymphomas

Utility of Systemic Staging in Low Grade B-Cell Lymphomas Presenting in the Skin

A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas

High-Depth, Targeted, Next Generation Sequencing Identifies Novel Genetic Alterations in Cutaneous T-Cell Lymphoma

Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL)

Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.

Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial.

Pralatrexate (PDX) IS Active in Cutaneous T-Cell Lymphoma: Preliminary Results of a Multi-Center Dose-Finding Trial.

Bexarotene Is Highly Active in the Treatment of Subcutaneous Panniculitis-Like T-Cell Lymphoma.

Results of a Phase II Trial of Oral Bexarotene Combined with Interferon Alfa-2b for Patients with Cutaneous T-Cell Lymphoma (CTCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only